1
|
Wei Y, Zhu X, Lin S, Yang W, Wang T, Nie X, Shi Z, Liu Z, Zhang R, Li D. Zinc gluconate improves atopic dermatitis by modulating CXCL10 release of keratinocytes via PPARα activation. Biomed Pharmacother 2024; 177:117129. [PMID: 39018874 DOI: 10.1016/j.biopha.2024.117129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 07/09/2024] [Accepted: 07/10/2024] [Indexed: 07/19/2024] Open
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin condition with complex causes involving immune factors. The presence of essential trace elements that support immune system function can influence the development of this condition. This study investigated how serum trace elements impact the pathogenesis of atopic dermatitis. Upon analyzing serum microelements in AD patients and control subjects, it was observed that patients with AD had notably lower zinc levels. Genomic analysis of AD skin revealed distinct gene expression patterns, specifically the increased expression of CXCL10 in the epidermis. The heightened levels of CXCL10 in AD skin lesions were found to correlate with reduced serum zinc levels. Treatment with zinc gluconate showed reduced chemotactic response and CXCL10 release, suggesting its potential to regulate CXCL10 expression of keratinocytes in AD. The mechanism behind this involved the downregulation of STAT phosphorylation through activating PPARα. In the AD-like dermatitis mouse model, zinc gluconate therapy decreased serum IgE levels, alleviated skin lesion severity, reduced skin thickness, and lowered CXCL10 expression, demonstrating its efficacy in managing AD-like skin conditions. These findings indicate that zinc gluconate can reduce inflammation in keratinocytes by activating PPARα, inhibiting STAT signaling, and decreasing CXCL10 release, thus highlighting its potential as a therapeutic target for AD.
Collapse
Affiliation(s)
- Yujia Wei
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Xiaomei Zhu
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Shan Lin
- Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| | - Wei Yang
- Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| | - Tingmei Wang
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Xiaoqi Nie
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Zeqi Shi
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Zhong Liu
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Ri Zhang
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| | - Dong Li
- Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China.
| |
Collapse
|
2
|
Markota Čagalj A, Markic J, Vuković D, Šitum Čeprnja Z, Gogić Salapić T, Buljan I, Pranić SM. Linguistic Validation and Reliability of the Croatian Version of the TOPICOP Questionnaire. MEDICINA (KAUNAS, LITHUANIA) 2024; 60:968. [PMID: 38929585 PMCID: PMC11205604 DOI: 10.3390/medicina60060968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 06/01/2024] [Accepted: 06/08/2024] [Indexed: 06/28/2024]
Abstract
Background and Objectives: This study demonstrates the factor structure and reliability of the Croatian version of the TOPICOP (Topical Corticosteroid Phobia) questionnaire, thereby contributing to further validation and standardization of the measurement of topical corticophobia with dermatological patients or their parents, which directly affects patient or parent compliance, as well as the final therapeutic effect. Materials and Methods: The cross-sectional, observational study was conducted at the University Hospital Centre Split, Department of Dermatovenerology. The research involved inviting 120 participants (age 12-68) who attended the University Hospital Centre Split's Atopy School, patients examined in the Dermatology Outpatient Clinic of the University Hospital Centre Split and diagnosed with atopic dermatitis (AD) or allergic contact dermatitis (ACD), and parents or legal representatives of patients younger than 12 years old. The TOPICOP questionnaire consists of 12 items assessing the three different components of topical corticophobia (worries, beliefs, and behaviour). Respondents evaluated their perception of the correctness of each statement within 10 min of filling out the questionnaire on a four-point Likert scale. Results: The response rate was 94%, resulting in a sample of 113 respondents (109 adults and 4 children). Factor analysis yielded one common factor of relatively high reliability (Cronbach α = 0.85, 95% CI 0.81 to 0.89). No differences were found in questionnaire scores between male and female participants, nor between the parents/legal representatives of dermatological patients and other patients. Conclusions: This research contributes to further development of the appropriate measuring instrument, its practical application, and thus, the better recognition, resolution, and prevention of topical corticophobia as part of the better overall healthcare and treatment of chronic dermatological patients.
Collapse
Affiliation(s)
- Adela Markota Čagalj
- Department of Dermatology and Venereology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia; (A.M.Č.); (Z.Š.Č.); (T.G.S.)
- School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia;
| | - Josko Markic
- School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia;
- Department of Pediatrics, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia
| | - Dubravka Vuković
- Department of Dermatology and Venereology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia; (A.M.Č.); (Z.Š.Č.); (T.G.S.)
- School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia;
| | - Zdenka Šitum Čeprnja
- Department of Dermatology and Venereology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia; (A.M.Č.); (Z.Š.Č.); (T.G.S.)
- School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia;
| | - Tina Gogić Salapić
- Department of Dermatology and Venereology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia; (A.M.Č.); (Z.Š.Č.); (T.G.S.)
- School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia;
| | - Ivan Buljan
- Department of Psychology, Faculty of Humanities and Social Sciences in Split, University of Split, Poljička cesta 35, 21000 Split, Croatia;
| | - Shelly Melissa Pranić
- Department of Public Health, School of Medicine, University of Split, Cohrane Croatia, Šoltanska 2, 21000 Split, Croatia;
| |
Collapse
|
3
|
Mo Z, Yuan J, Guan X, Peng J. Advancements in Dermatological Applications of Curcumin: Clinical Efficacy and Mechanistic Insights in the Management of Skin Disorders. Clin Cosmet Investig Dermatol 2024; 17:1083-1092. [PMID: 38765192 PMCID: PMC11100965 DOI: 10.2147/ccid.s467442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Accepted: 05/04/2024] [Indexed: 05/21/2024]
Abstract
Curcumin, derived from Curcuma longa (turmeric), exhibits significant potential in dermatology, addressing conditions like atopic dermatitis, psoriasis, chronic wounds, skin cancer, and infections through its anti-inflammatory, antioxidant, anticancer, and antimicrobial properties. This review synthesizes evidence on curcumin's mechanisms, including modulation of immune responses and promotion of wound healing, showcasing its efficacy in reducing inflammation, cytokine levels, and enhancing skin barrier functions. Studies highlight curcumin's ability to selectively target tumor cells, suggesting a multifaceted approach to cancer therapy with minimal side effects. Despite promising therapeutic benefits, challenges remain in bioavailability, potency, and targeted delivery, underscoring the need for further research to optimize dosages, delivery methods, and assess long-term safety. The integration of curcumin into dermatological practice requires a balanced consideration of evidence-based efficacy and safety. Curcumin's comprehensive utility in dermatology, coupled with the necessity for advanced scientific exploration, emphasizes the importance of combining traditional knowledge with contemporary research to improve patient care in dermatology. This approach could significantly enhance outcomes for individuals with skin-related conditions, marking curcumin as a versatile and promising agent in the field.
Collapse
Affiliation(s)
- Zhiming Mo
- Department of Pharmaceutical Center, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People’s Republic of China
| | - Jiayi Yuan
- Department of Pharmaceutical Center, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People’s Republic of China
| | - Xuelian Guan
- Department of Pharmaceutical Center, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People’s Republic of China
| | - Jianhong Peng
- Department of Internal Medicine, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People’s Republic of China
| |
Collapse
|
4
|
Luan X, Cui X, Fan L, Wang Z, Luo D. No Evidence of Causal Association Between Atopic Dermatitis and Primary Open-Angle Glaucoma: A Bidirectional Two-Sample Mendelian Randomization Study. Dermatitis 2024. [PMID: 38394273 DOI: 10.1089/derm.2023.0380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2024]
Abstract
Background: Atopic dermatitis (AD) can present with open-angle glaucoma, but powerful evidence to support their causal relationship is absent. Objective: To investigate the causal association of AD with primary open-angle glaucoma (POAG). Methods: A bidirectional 2-sample Mendelian randomization (MR) study was performed with the software R. Results: Eighteen single nucleotide polymorphisms (SNPs) were used in the forward MR analysis with AD as exposure. The inverse-variance weighted (IVW) method produced a result that genetically predicted AD was not associated with POAG (odds ratio [OR] = 1.10, 95% confidence interval [CI]: 0.95-1.27, P = 0.215). Fifty-one SNPs were used in the reverse MR analysis with POAG as exposure. The IVW method yielded a result that genetically predicted POAG was not correlated with AD (OR = 0.98, 95% CI: 0.95-1.01, P = 0.191). The bidirectional causal effect estimates were consistent with supplementary MR methods (MR-Egger, weighted median, simple mode, and weighted mode). The sensitivity analysis showed stable results. Conclusions: This bidirectional 2-sample MR study did not give evidence of causal association between AD and POAG.
Collapse
Affiliation(s)
- Xingbao Luan
- From the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Xiaomei Cui
- From the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Lipan Fan
- From the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Zhaopeng Wang
- From the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Dan Luo
- From the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
5
|
Weil C, Adiri R, Chodick G, Gersten M, Cohen Barak E. Trends of Diagnosis, Disease Course, and Treatment of Atopic Dermatitis 2012-2021: Real-World Data from a Large Healthcare Provider. J Clin Med 2024; 13:281. [PMID: 38202289 PMCID: PMC10779695 DOI: 10.3390/jcm13010281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 12/31/2023] [Accepted: 01/02/2024] [Indexed: 01/12/2024] Open
Abstract
In the last decade, new treatments for atopic dermatitis (AD) have emerged. We aimed to describe trends of the diagnosis, disease course, and treatment of AD over a decade (2012-2021) using data from Maccabi Healthcare Services (a 2.7-million-member healthcare provider in Israel). The AD prevalence was stable (4.0% on 31 December 2021 vs. 4.3% on 31 December 2012). The annual AD incidence was also stable (5.8/1000 in 2012 and 5.7/1000 in 2021). AD-related treatment use was highest in the first year post-diagnosis, and it included, among children (n = 87,414) vs. adults (n = 36,865), low-potency topical corticosteroids (TCS) (41.8% vs. 27.1%), mid-potency TCS (30.1% vs. 28.1%), high-potency TCS (34.9% vs. 60.3%), topical calcineurin inhibitor (10.8% vs. 10.1%), phosphodiesterase-4-inhibitor (0.3% vs. 0.7% overall; approved in 2019), phototherapy (0.1% vs. 2.3%), and systemic/biologic treatments (13.0% vs. 13.3%). Among children diagnosed in 2012 and followed through to 2021 (n = 5248), 21.5% had ≥1 AD diagnosis/treatment 10 years later (among 3223 adults: 38.3%). We conclude that the incidence and prevalence rates of AD were comparable to those in similar database studies and remained relatively stable over the past decade. The results underscore the burden of medication use among children and adults, particularly in the first year after AD diagnosis, and the low rate of AD diagnosis among patients originally diagnosed as children 10 years earlier.
Collapse
Affiliation(s)
- Clara Weil
- Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 68125, Israel
| | - Roni Adiri
- Pfizer Pharmaceuticals Israel Ltd., Herzliya 4672509, Israel
| | - Gabriel Chodick
- Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 68125, Israel
- School of Public Health, Faculty of Medicine, Tel Aviv University, Ramat Aviv 6997801, Israel
| | - Merril Gersten
- Pfizer Pharmaceuticals Israel Ltd., Herzliya 4672509, Israel
| | - Eran Cohen Barak
- Department of Dermatology, Emek Medical Center, Afula 18101, Israel
- Bruce and Ruth Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa 3200003, Israel
| |
Collapse
|